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Introduction
The BRAF gene encodes serine/threonine kinase
activated by somatic point mutations in human
cancers. K-Ras and B-Raf are involved in the
transduction of mitogenic signals from the cell
membrane to the nucleus. Recent clinical trials
indicate that BRAF mutations are associated with
resistance to anti-EGFR antibodies in colorectal
cancers with wild-type KRAS [1-3]. Moreover,
several drugs targeting B-Raf are in development or
currently in clinical trials, including selective
V600E-mutant inhibitors [4, 5]. Depending on
therapeutic approach, BRAF mutations may serve as
an exclusion or inclusion criterion; thus they
constitute an important predictive factor. Allele-
specific PCR is frequently in use for V600E mutation
detection based on an assumption that this mutation
is predominant; however, rare mutations in other
codons are omitted. 
Here we present the results of SSCP and
sequencing analysis of exons 11 and 15 of the BRAF
gene in routinely resected sporadic colorectal cancers
previously screened for KRAS mutations.
Materials and methods
Samples
One hundred and sixty-three unselected sporadic
colorectal carcinoma cases were studied. All the
patients (91 men and 72 women, aged 34-87 years)
underwent surgery at the 1st Department of Surgery,
Collegium Medicum, Jagiellonian University, Kraków,
Poland. Carcinomas were histologically staged
according to the TNM classification. The tumour
and normal mucosa samples were cut into small
pieces, snap frozen and stored at –80°C for further
investigation. DNA was extracted from fresh-frozen
tumour and corresponding non-neoplastic tissues
according to the manufacturer’s instructions
(QIAamp DNA Mini Kit, Qiagen).
Mutation detection 
Mutational analysis of BRAF was performed by
SSCP and sequencing. PCR products were amplified
with RedTaq polymerase (Sigma-Aldrich) using the
primers:
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BRAF mutations are second to KRAS mutations in activation of the MAPK
pathway in colorectal carcinoma cells. In addition to mutated KRAS, BRAF
V600E mutation is associated with resistance to EGFR-targeted therapy in
colorectal cancer; thus mutated BRAF might serve as a predictive factor. In this
study, 163 routinely resected adenocarcinomas were screened for mutations in
exons 11 and 15 of the BRAF gene. Only 6 (3.7%) tumours had a missense point
mutation (G469A, D594G, G596R, K601N and twice V600E). The tumours
were locally advanced with multiple metastases to lymph nodes. Mutations were
associated with microsatellite instability (2 cases MSI-H, 2 cases MSI-L) and
mutually exclusive with a mutated KRAS gene. In this sample set, mutations in
the BRAF gene were more diverse and less frequent than usually reported.
Key words: BRAF, mutations, colorectal cancer.
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Table I. Tumours with BRAF mutation
MUTATION LOCATION MSI STATUS TNM DIFFERENTIATION
p.G469A (c.1406G>C) Rectum MSS T2N1M0 Poor
p.D594G (c.1781A>G) Rectum MSI-L T4N2M0 Moderate
p.G596R (c.1786G>C) Right colon MSI-H T3N2M0 Moderate
p.V600E (c.1799T>A) Right colon MSI-H T3N2M0 Poor
p.V600E (c.1799T>A) Left colon MSS T3N2M0 Poor
p.K601N (c.1803A>T) Left colon MSI-L T3N2M0 Moderate
5'-TTCTGTTTGGCTTGACTTGACTT
5'-ACTTGTCACAATGTCACCACATT 
for BRAF exon 11 [6] and 
5'-TCATAATGCTTGCTCTGATAGGA 
5'-GGCCAAAAATTTAATCAGTGGA for BRAF
exon 15 [7] (annealing temp. 57°C). Electrophoresis was
carried out in TBE buffer (MP Biomedicals) using 80%
MDE gels (Cambrex Bio Science). Thermostatically
controlled circulating water was used to maintain a
constant temperature of 8°C. Gels were run for 18 h with
constant 170 V and developed by silver staining.
Mutations were confirmed by direct sequencing. The
sequence data were collected and analysed using an ABI
PRISM 310 Genetic Analyzer (Applied Biosystems).
KRAS mutations were detected by SSCP and sequencing
as described in detail previously [8].
MSI analysis
PCR was performed according to the previously
reported protocol using a panel of 5 microsatellite
markers located near APC, p53, BATRII, BAT26,
and BAX [9]. All the cases that demonstrated MSI
or LOH in at least 1 microsatellite marker were
examined with a panel of 9 microsatellite markers
(D2S123, D5S346, D3S1611, D18S35, NM-23,
D7S501, D1S2883, TP53-pentanucleotide, TP53-
dinucleotide) using a set of primers labelled with
fluorescent dyes. The PCR products were separated
on an ABI PRISM 310 Genetic Analyzer (Applied
Biosystems). According to the MSI/LOH results, the
cancers were classified into 3 groups: MSS
(microsatellite stable cancers, without detectable
instability), MSI-high (at least 40% unstable
markers), and MSI-low [10].
Results
Mutational analysis performed on 163 sporadic
colorectal adenocarcinoma cases revealed BRAF
mutations in 6 tumours (3.7%). All of these
mutations were missense. Five mutations were
localized in exon 15: D594G, G596R, K601N and
twice V600E. Only 1 mutation was detected in exon
11 (G469A). 
Tumours with mutation in exon 15 were locally
advanced (T3 or T4) at the time of resection. The
only tumour with mutation in exon 11 was invading
a muscular tissue (T2). All were metastatic to lymph
nodes without diagnosed distant metastases. 
A BRAF mutation was detected in only 2 of 14 MSI-
H cancers (Fisher’s test MSI-H vs. MSS/MSI-L; 
p = 0.08). These 2 mutated tumours with a high
level of microsatellite instability had typical right-
sided location and moderate or poor differentiation.
Four others were situated distally to the splenic
flexure with stable microsatellites (MSS) or a low
level of instability (MSI-L) and moderate to poor
differentiation. No mutation was detected in well
differentiated tumours, which made up 25%
(41/163) of the specimens. Tumours with V600E as
well as exon 11 mutations were poorly differentiated.
Mucus production characterized 19% (31/163) of
collected adenocarcinomas and none of them carried
a BRAF mutation whereas 45% (14/31) had a KRAS
mutation. Mutated KRAS was detected in 36%
(58/163) of the specimens  [8]. The BRAF and
KRAS mutations were mutually exclusive.
Discussion 
Oncogenes BRAF and KRAS play a role in
increased activity of the MAPK pathway, which is
involved in cancer cell proliferation and migration.
Due to mutations, altered B-Raf kinase may
influence therapy outcome as it does in EGFR
inhibition refractory colorectal cancers. BRAF
mutation testing can provide useful information for
planning therapy for individual patients. The
reported frequency of mutations varies in sporadic
colorectal cancers between 3 and 21% (Table II). In
our study, the incidence was one of the lowest 
in unselected samples. A mutation was observed only
in 3.7% of the collected tumours. 
Allele-specific PCR is usually employed for
detection of the most common mutation in codon
600. Interestingly, V600E mutation was not
predominant in this sample set: only 2 out of 
6 mutations (33%). Yuen et al. reported a similar
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Table III. Studies with exons 11 and 15 analysis of BRAF gene in colorectal cancer 
STUDY [REFERENCE] FREQUENCY OF V600E IN BRAF FREQUENCY OF EXON 11 
MUTATION CASES (%) MUTATIONS IN BRAF MUTATION CASES (%)
Yuen et al. 2002 [15] 36 18
Lubomierski et al. 2005 [27] 50 14
Suehiro et al. 2008 [16] 69 15
Ahlquist et al. 2008 [28] 79 6
Ikehara et al. 2005 [17] 83 17
Rajagopalan et al. 2002 [20] 88 9
Wang et al. 2003 [29] 95 2
TABLE II. BRAF MUTATION FREQUENCIES IN UNSELECTED SPECIMENS OF COLORECTAL CANCER
STUDY [REFERENCE] NO. OF CASES % (NO.) WITH BRAF MUTATION GENE FRAGMENT TESTED
Miranda et al. 2006  [11] 202 3.5 (7) V600E only
Maestro et al. 2007  [12] 324 3.7 (12) V600E only
Lee et al. 2008 [13] 134 4.5 (6) V600E only
Asaka et al. 2009 [14] 908 4.5 (41) V600E only
Yuen et al. 2002 [15] 215 5.1 (11) Exons 11 and 15
Suehiro et al. 2008  [16] 199 6.5 (13) Exons 11 and 15
Ikehara et al. 2005  [17] 82 7.3 (6) Exons 11 and 15
Nagasaka et al. 2004 [18] 234 9.0 (21) V600E only
Samowitz et al. 2005 [19] * 911 9.5 (87) V600E only
Rajagopalan et al. 2002  [20] 330 9.7 (32) Exons 11 and 15
Deng et al. 2004  [21] 80 10.0 (8) V600E **
Shen et al. 2007  [22] 87 12.6 (11) Exons 11 and 15 
Barault et al. 2008 [23] * 585 13.3 (78) V600E only
Weisenberger et al. 2006 [24] 187 13.9 (26) V600E only
Ogino et al. 2006  [25] 837 14.1 (118) V600E only
Goel et al. 2007 [26 ] 126 20.6 (26) V600E only
* colon cancers only; ** mutation-specific PCR for V600E detection in 65 tumours and sequencing of 2 exons in 15 tumours.
proportion (36%) [15]. Some authors have analysed
2 exons of the BRAF gene. The percentage of V600E
mutations varied between 36% and 95% of the
BRAF mutations in such studies (Table III). In our
study, exon involvement resembled already
published data. Five mutations in exon 15 (codons
594–601) and only 1 in exon 11 (codon 469) were
observed. Mutations in exon 11 occurs rarely.
Depending on the cohort studied, the percentage of
mutations in exon 11 fluctuated between 2% and
18% of all BRAF mutations (Table III).
Many authors have reported a high incidence of
BRAF mutations in MSI-H cancers: Maestro et al.
18.4% [12], Lubomierski et al. 27% [27],
Rajagopalan et al. 30.6% [20], Asaka et al. 32%
[14], Nagasaka et al. 45% [18], Samowitz et al. 52%
[19], Ahlquist et al. 62% [28], Barault et al. 63%
[23], Goel et al. 71% [26]. The association with 
a high level of microsatellite instability is well
established. However, in the present study, BRAF
mutations were relatively rare in MSI-H cancers
(14%). The trend towards higher incidence in this
group is statistically insignificant in comparison with
MSS. No BRAF mutation has been detected in well
differentiated carcinomas. An association of mutated
BRAF with poor differentiation is sometimes
reported [18, 19]. Contrary to published data, none
of the 6 tumours with mutation had mucinous
histology [19, 30, 31].
Oncogenic mutation in either KRAS or BRAF is
usually sufficient for dysregulation of the MAPK
pathway in a cancer cell. Coexisting mutations in
both genes are rare findings [15, 19]. Our results
support this observation. No tumour with mutated
BRAF had concomitant mutated KRAS.
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